Literature DB >> 21237283

Phenothiazine: the seven lives of pharmacology's first lead structure.

Maike J Ohlow1, Bernd Moosmann.   

Abstract

Rooted in the early days of organic dye chemistry, the phenothiazine structure and its derivatives have since held a prominent place in pharmacology and biomedicine. Initially used for histochemical stains of plasmodia by Paul Ehrlich, anthelmintic and antibiotic properties of phenothiazines were globally exploited in the 1930s and 1940s. Clinical use of N-substituted phenothiazines as antihistaminics (1940s), sedatives and antipsychotics (1950s) followed and continues to this day. Recently, interest in these structures has re-emerged for a variety of fascinating features in relation to neurodegenerative disease, spearheaded by the unique redox chemistry of phenothiazine--arguably the most potent chain-breaking antioxidant ever identified.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21237283     DOI: 10.1016/j.drudis.2011.01.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  43 in total

Review 1.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

Review 2.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

Review 3.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 4.  Dual oxidase: a novel therapeutic target in allergic disease.

Authors:  Albert van der Vliet; Karamatullah Danyal; David E Heppner
Journal:  Br J Pharmacol       Date:  2018-03-15       Impact factor: 8.739

5.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

Review 6.  Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.

Authors:  Rafael Tabarés-Seisdedos; John L Rubenstein
Journal:  Nat Rev Neurosci       Date:  2013-04       Impact factor: 34.870

Review 7.  The oxidative stress theory of disease: levels of evidence and epistemological aspects.

Authors:  Pietro Ghezzi; Vincent Jaquet; Fabrizio Marcucci; Harald H H W Schmidt
Journal:  Br J Pharmacol       Date:  2016-08-04       Impact factor: 8.739

8.  Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.

Authors:  Maike J Ohlow; Selina Sohre; Matthias Granold; Mathias Schreckenberger; Bernd Moosmann
Journal:  Pharm Res       Date:  2016-11-28       Impact factor: 4.200

9.  Neuroprotective and Functional Improvement Effects of Methylene Blue in Global Cerebral Ischemia.

Authors:  Qing Lu; Donovan Tucker; Yan Dong; Ningjun Zhao; Quanguang Zhang
Journal:  Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.590

10.  Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease.

Authors:  Robert E Molokie; Diana J Wilkie; Harriett Wittert; Marie L Suarez; Yingwei Yao; Zhongsheng Zhao; Ying He; Zaijie J Wang
Journal:  Eur J Pharmacol       Date:  2013-11-07       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.